mRNA-Based Therapeutics in Cancer Treatment
Pharmaceutics · 13.02.2023 · 15 (2) · 622
DOI: 10.3390/pharmaceutics15020622 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 13.02.2023. Verfasst von Han Sun und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong Univer…. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 276 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Jiao Tong University Medical-Engineering interdisciplinary research key projects, National Key R&D Program of China, National Key R&D Program of China.
Abstract (Originalsprache)
Over the past two decades, significant technological innovations have led to messenger RNA (mRNA) becoming a promising option for developing prophylactic and therapeutic vaccines, protein replacement therapies, and genome engineering. The success of the two COVID-19 mRNA vaccines has sparked new enthusiasm for other medical applications, particularly in cancer treatment. In vitro-transcribed (IVT) mRNAs are structurally designed to resemble naturally occurring mature mRNA. Delivery of IVT mRNA via delivery platforms such as lipid nanoparticles allows host cells to produce many copies of encoded proteins, which can serve as antigens to stimulate immune responses or as additional beneficial proteins for supplements. mRNA-based cancer therapeutics include mRNA cancer vaccines, mRNA encoding cytokines, chimeric antigen receptors, tumor suppressors, and other combination therapies. To better understand the current development and research status of mRNA therapies for cancer treatment, this review focused on the molecular design, delivery systems, and clinical indications of mRNA therapies in cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
- Department of Oral Maxillofacial & Head and Neck Oncology, National Center of Stomatology, National Clinical Research Center for Oral Disease, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Me…
- Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
ORCID-Profile: Yu Zhang, Ge Wang, Yingjie Xu
Förderung
- Shanghai Jiao Tong University Medical-Engineering interdisciplinary research key projects
- National Key R&D Program of China
- National Key R&D Program of China
Zitieren
APA
Sun, H., Zhang, Y., Wang, G., Yang, W., & Xu, Y. (2023). mRNA-Based Therapeutics in Cancer Treatment. Pharmaceutics, 15(2), 622. https://doi.org/10.3390/pharmaceutics15020622
Vancouver
Sun H, Zhang Y, Wang G, Yang W, Xu Y. mRNA-Based Therapeutics in Cancer Treatment. Pharmaceutics. 2023;15(2):622. doi:10.3390/pharmaceutics15020622
BibTeX
@article{Sun2023,
author = {Sun, Han and Zhang, Yu and Wang, Ge and Yang, Wen and Xu, Yingjie},
title = {mRNA-Based Therapeutics in Cancer Treatment},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {2},
pages = {622},
doi = {10.3390/pharmaceutics15020622}
}
EUVIMED